

**22nd Century Group, Inc. (XXII - \$2.79 - Buy)**

**COMPANY NOTE**

**JAMES McILREE, CFA**, Senior Research Analyst, +1-646-465-9034  
 jmcilree@chardan.com


**Sales and trading** 7 a.m. to 7 p.m. ET, (646) 465-9090  
**Sales and trading** 7 p.m. to 7 a.m. ET, (646) 465-9063

Stock Data	03/09/18
Price	\$2.79
52 Week Range	(\$0.89 - \$4.44)
Price Target	\$11.50
Market Cap (mil)	\$346.35
Shares out (mil)	124.14
3-Mo Avg Vol	4,055,548
Cash per share	\$0.50
Total Debt (mil)	\$0.00

Revenues (\$ millions)					
Yr Dec	2017A	2018E		2019E	
	Actual	Curr	Prev	Curr	Prev
Mar	2.2	-	-	-	-
Jun	3.9	-	-	-	-
Sep	4.5	-	-	-	-
Dec	5.9	-	-	-	-
YEAR	16.6	16.0	-	16.0	-

EPS (\$)					
Yr Dec	2017A	2018E		2019E	
	Actual	Curr	Prev	Curr	Prev
Mar	(0.03)	-	-	-	-
Jun	(0.03)	-	-	-	-
Sep	(0.03)	-	-	-	-
Dec	(0.03)	-	-	-	-
YEAR	(0.13)	(0.11)	-	(0.11)	-

**One year price history XXII**



**Two Pending Catalysts: FDA ANPRM and Hatsukami Study Publication**

Next up for 22nd Century will be publication of the FDA's Advanced Notice of Proposed Rulemaking (ANPRM) that will take the initial regulatory steps that could ultimately result in a product standard that sets a maximum nicotine level in cigarettes to non-addictive levels. This is one of three ANPRM's submitted by the FDA to the Office of Information and Regulatory Affairs, part of the Office of Management and Budget. The other two ANPRMs deal with 1) the role of flavors in tobacco products in attracting youth to smoking and getting smokers to switch to less harmful forms of nicotine delivery and 2) the public health impacts of premium cigars. Usually the publication of the ANPRM happens soon after submission to OMB, but in unusual circumstances we have seen it take a couple of months.

A comment period follows publication of the ANPRM in the Federal Register. Sixty days is common, but often for complex and significant rules a longer period may be allowed, possibly up to 180 days. After comments are received the FDA will evaluate the comments as well as the ex parte meetings with interested parties. The ANPRM can be followed by an NPRM, or a final rule. The entire process can typically take 12-24 months, longer for the more consequential rules, such as this could be.

Another pending catalyst for the shares is the publication of results from a study led by Dr. Dorothy Hatsukami of a 1,250 patient, 20-week study evaluating smoking cessation strategies on three cohorts of smokers using 22nd Century's SPECTRUM cigarettes. One group used Very Low Nicotine (VLN) cigarettes, another group gradually reduced their nicotine content and a third group used cigarettes with normal nicotine content. Preliminary results showed use of VLN cigarettes immediately is the "most likely to lead to less harm," and has a "greater likelihood of more rapid smoking cessation." Since this is the focus of the FDA's regulatory process, the publication of this study will bolster the FDA's desire to set maximum nicotine standards in cigarettes.

It is important for regulatory agencies to build a case that overcomes the inevitable objections by industry participants, public policy advocates, the general public and Congress. The Hatsukami study joins a large body of evidence very-low nicotine cigarettes can reduce the harm from cigarettes and lead to greater rates of smoking cessation.

There are some who believe the market is moving to other nicotine delivery systems, like e-cigs, which probably are less harmful than combustible cigarettes and could escape the FDA's oversight. We disagree. The research shows 90% of smokers start by age 18, 95% by 21 and 99% before they reach 26. Because of this the FDA places significant emphasis on programs and policies that reduce the incidence of smoking by the

young, and we expect will be skeptical of products that offer a path for the young to become addicted.

Regulatory changes in the US will likely be a precursor to changes in other jurisdictions. 22nd Century indicates Canada, New Zealand, Finland and the UK are investigating nicotine reduction strategies. Our price target only includes an assumption of changes in the US.

The company's quarterly burn is between \$3 and \$3.5 million. This can change as the process with the FDA progresses. There may be increased costs in hiring personnel and working with the FDA and third-parties in making known 22nd Century's capabilities in the market. Additionally, we believe the company will need to protect and advance its technology which could result in higher R&D and G&A. To date, most of the company's revenues have been generated by contract manufacturing, and the company intends to continue growing this business. In Q4 positive gross margin was achieved and this should increase as volumes rise, but contract manufacturing will always be a low margin business. For now, we are estimating revenue and income for the coming years similar to 2017 levels.

Cash will be critical. The FDA process could be long and expensive depending on additional studies that may be required to build the record as well as personnel to make 22nd Century's technology known by the relevant constituents to the FDA's nicotine limiting initiative.

We maintain our Buy recommendation on 22nd Century and reiterate our 12-month price target of \$11.50. We believe 22nd Century's patents, covering nicotine regulation in tobacco plants, is a solution to the FDA's pending regulation of nicotine levels in combustible cigarettes. We believe XXII has the opportunity to license its technology to Big Tobacco at a fraction of the cost they are currently contemplating it will take to comply with potential FDA regulations and this could result in a royalties or licensing stream far surpassing today's market cap. While our price target is based on changes in the US market we expect other countries to follow the FDA's lead, opening up additional markets for XXII and higher expected value for the shares.

### **Valuation:**

Our twelve-month price target of \$11.50 is based on the company garnering royalty revenue for its technology on 10% of the US market share in the next five years, discounted at a 20% annual rate.


### **Risks to achievement of target price:**

Risks to achieving our price target include delays in the FDA process, ability to find partners for X-22, challenges in attracting contract manufacturing and selling product overseas and possibility of requiring additional capital.

### **Company description:**

22nd Century owns or exclusively controls over 200 issued patents, 50 pending patent applications. The company's proprietary technology enables the control of nicotine levels in tobacco plants by controlling the genes responsible for nicotine production in tobacco plants.

## Required Research Disclosures



### Distribution of Ratings/IB Services Chardan Capital Markets

Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY [BUY]	68	68.69	29	42.65
HOLD [NEUTRAL]	24	24.24	2	8.33
SELL [SELL]	0	0.00	0	0.00
NOT RATED [NR]	7	7.07	0	0.00

### Regulation Analyst Certification ("Reg AC") —

**ANALYST(S) CERTIFICATION:** The analyst(s) responsible for covering the securities in this report certify that the views expressed in this research report accurately reflect their personal views about "Company" and its securities. The analyst(s) responsible for covering the securities in this report certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation or view contained in this research report.

### DISCLOSURES

Within the last twelve months, Chardan Capital Markets has received compensation for investment banking services from 22nd Century Group, Inc.. This research contains forward looking statements made pursuant to the safe harbor provision of Private Securities Litigation Act of 1995.

Within the past 12 months Chardan Capital Markets has managed or co-managed a public offering for 22nd Century Group, Inc..

### RATINGS

**Buy:** Expected to materially outperform sector average over 12 months and indicates total return of at least 10% over the next 12 months.

**Neutral:** Returns expected to be in line with sector average over 12 months and indicates total return between negative 10% and 10% over the next 12 months.

**Sell:** Returns expected to be materially below sector average over 12 months and indicates total price decline of at least 10% over the next 12 months.

### 22nd Century Group, Inc. (XXII - \$2.79 - Buy)

Price Target                      \$11.50

### VALUATION:

Our twelve-month price target of \$11.50 is based on the company garnering royalty revenue for its technology on 10% of the US market share in the next five years, discounted at a 20% annual rate.

**RISKS TO ACHIEVEMENT OF TARGET PRICE:**

Risks to achieving our price target include delays in the FDA process, ability to find partners for X- 22, challenges in attracting contract manufacturing and selling product overseas and possibility of requiring additional capital.

**FORWARD- LOOKING STATEMENTS:** This Report contains forward- looking statements, which involve risks and uncertainties. Actual results may differ significantly from such forward- looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the “Risk Factors” section in the SEC filings available in electronic format through SEC Edgar filings at [www.SEC.gov](http://www.SEC.gov) on the Internet.

**COMPENSATION OR SECURITIES OWNERSHIP:** The analyst(s) responsible for covering the securities in this report receives compensation based upon, among other factors, the overall profitability of Chardan Capital Markets including profits derived from investment banking revenue and securities trading and market making revenue. The analyst(s) that prepared the research report did not receive any compensation from the Company or any other companies mentioned in this report in connection with the preparation of this report. The analysts responsible for covering the securities in this report currently do not own common stock in the Company, but in the future may from time to time engage in transactions with respect to the Company or other companies mentioned in the report.

For compendium reports (a research report covering six or more subject companies) please see the latest published research to view company specific disclosures.

**GENERAL:** This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell a solicitation of an offer to buy or sell any financial instruments or to particular trading strategy in any jurisdiction. The information and opinions in this report were prepared by registered employees of Chardan Capital Market. The information herein is believed by Chardan Capital Market to be reliable and has been obtained from public sources believed to be reliable, but Chardan Capital Market makes no representation as to the accuracy or completeness of such information. Opinions, estimates and projections in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of Chardan Capital Market and are subject to change without notice. In addition, opinions, estimates and projections in this report may differ from or be contrary to those expressed by other business areas or group of Chardan Capital Market and its affiliates. Chardan Capital Market has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Chardan Capital Market does not provide individually tailored investment advice in research reports. This report has been prepared without regard to the particular investments and circumstances of the recipient. The securities discussed in this report may not be suitable for all investors and investors must make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives. Estimates of future performance are based on assumptions that may not be realized. Furthermore, past performance is not necessarily indicative of future performance.

Chardan Capital Market salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed in this research. Chardan Capital Markets may seek to offer investment banking services to all companies under research coverage.

Electronic research is simultaneously available to all clients. This report is provided to Chardan Capital Market clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Chardan Capital Market. Receipt and review of this research report constituted your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion or information contained in this report (including any investment recommendations, estimates or target prices) without first obtaining express permission from Chardan Capital Market.

This report is not intended for distribution to, or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

For investors in the UK: In making this report available, Chardan Capital Market makes no recommendation to buy, sell or otherwise deal in any securities or investments whatsoever and you should neither rely or act upon, directly or indirectly, any of the information contained in this report in respect of any such investment activity. This report is being directed at or distributed to , (a) persons who fall within the definition of Investment Professionals (set out in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”)); (b) persons falling within the definition of high net worth companies, unincorporated associations, etc. (set out in Article 49(2) of the Order); (c) other

persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). This report must not be acted on or relied on by persons who are not relevant persons.